These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63 related articles for article (PubMed ID: 11152049)
1. The unblind leading the blind: the Achilles heel of too many trials. Reilly D J Altern Complement Med; 2000 Dec; 6(6):479-80. PubMed ID: 11152049 [No Abstract] [Full Text] [Related]
2. Integrity and research: introducing the concept of dual blindness. how blind are double-blind clinical trials in alternative medicine? Caspi O; Millen C; Sechrest L J Altern Complement Med; 2000 Dec; 6(6):493-8. PubMed ID: 11152053 [TBL] [Abstract][Full Text] [Related]
3. The placebo response in clinical trials-the current state of play. Enck P; Klosterhalfen S Complement Ther Med; 2013 Apr; 21(2):98-101. PubMed ID: 23497810 [TBL] [Abstract][Full Text] [Related]
4. Something fishy: the issue of omega-3 blinding in psychiatric clinical trials. Liu JC; Ang RP; Fung DS Aust N Z J Psychiatry; 2013 Mar; 47(3):201-5. PubMed ID: 23463077 [No Abstract] [Full Text] [Related]
5. Blinding and the tapestry of trial design: revealing the weaving and the woven. Jobst KA J Altern Complement Med; 2000 Dec; 6(6):475-7. PubMed ID: 11152048 [No Abstract] [Full Text] [Related]
6. Adverse events appear to unblind clinical trials in irritable bowel syndrome. Shah E; Triantafyllou K; Hana AA; Pimentel M Neurogastroenterol Motil; 2014 Apr; 26(4):482-8. PubMed ID: 24350975 [TBL] [Abstract][Full Text] [Related]
12. Is homoeopathy a placebo? Ernst E Br J Clin Pharmacol; 1990 Aug; 30(2):173-4. PubMed ID: 2206780 [No Abstract] [Full Text] [Related]
13. The nature and power of the placebo effect. Miller FG; Rosenstein DL J Clin Epidemiol; 2006 Apr; 59(4):331-5. PubMed ID: 16549251 [TBL] [Abstract][Full Text] [Related]
14. Reactions to treatment debriefing among the participants of a placebo controlled trial. Di Blasi Z; Crawford F; Bradley C; Kleijnen J BMC Health Serv Res; 2005 Apr; 5(1):30. PubMed ID: 15847683 [TBL] [Abstract][Full Text] [Related]
15. [The course of patients treated with placebo in trials of maintenance treatment of rheumatoid arthritis. Consequences for phase II studies]. Méry C; George N; de Géry A; Job-Deslandre C; Menkès CJ; Amor B Rev Rhum Mal Osteoartic; 1990 Feb; 57(2):119-22. PubMed ID: 2181611 [No Abstract] [Full Text] [Related]
16. [Acupuncture study of national health insurance technicians. Blinded too early!]. Wettig D MMW Fortschr Med; 2005 Jun; 147(24):13. PubMed ID: 16001525 [No Abstract] [Full Text] [Related]
17. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Rief W; Bingel U; Schedlowski M; Enck P Clin Pharmacol Ther; 2011 Nov; 90(5):722-6. PubMed ID: 21975346 [No Abstract] [Full Text] [Related]
18. [Arthroscopy and knee osteoarthritis: only a placebo effect?]. Ohnsorge JA; Maus U; Weisskopf M; Laskin RS Z Orthop Ihre Grenzgeb; 2006; 144(3):241-3. PubMed ID: 16821165 [No Abstract] [Full Text] [Related]
19. Growing placebo response rate: the problem in recent therapeutic trials? Uhlenhuth EH; Matuzas W; Warner TD; Thompson PM Psychopharmacol Bull; 1997; 33(1):31-9. PubMed ID: 9133749 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Keefe RS; Malhotra AK; Meltzer HY; Kane JM; Buchanan RW; Murthy A; Sovel M; Li C; Goldman R Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]